I promise that I don't have a contract that specifies a minimum number of Salix Pharmaceuticals (NASDAQ: SLXP )
articles, but sometimes the news flow just seems to run that way.
After a vague announcement of positive phase 3 data on Xifaxan in IBS-D
on July 1 and the announcement of a tax inversion M&A transaction
with Cosmo Tech on July 9, management has
now announced a successful appeal to the FDA and the approval of sub-q
Relistor for opioid-induced constipation (or OIC) in patients with
chronic pain unrelated to cancer.
Read the full article here:
Can Anything Derail Salix Pharmaceuticals?
No comments:
Post a Comment